Who Paid My Doc
David Newman
Endocrinology, Diabetes & Metabolism Fargo, ND Medical Doctor
NPI 1770759227 CMS profile 471060
2400 32Nd Ave S, Fargo, ND 58103
General payments
$134
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, David Newman of Fargo, ND is reported in the CMS Open Payments database as having received $134 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 15th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $121 | 2 | |
| 2019 | General | $13 | 1 |
Beside peers
- David Newman
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to David Newman were reported at $121. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | David Newman | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $13 | $494 | $123–$2,253 | $163 |
| 2020 | $0 | $335 | $85–$1,841 | $114 |
| 2021 | $0 | $398 | $88–$1,981 | $132 |
| 2022 | $0 | $364 | $88–$1,568 | $149 |
| 2023 | $0 | $420 | $113–$1,614 | $160 |
| 2024 | $0 | $440 | $121–$1,646 | $164 |
| 2025 | $121 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 29 drugsPart D claims
1,241
Drug cost
$69,474
Branded share of claims
12.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 14 | $17,610 | |
| Testosterone | Generic | 107 | $15,800 | |
| Levothyroxine Sodium | Generic | 368 | $5,773 | |
| Novolog Flexpen Insulin Aspart | Brand | 13 | $5,121 | |
| Hydrocortisone | Generic | 71 | $4,692 | |
| Synthroid Levothyroxine Sodium | Brand | 34 | $3,975 | |
| Estradiol | Generic | 70 | $2,584 | |
| Testosterone Cypionate | Generic | 68 | $2,456 | |
| Tirosint Levothyroxine Sodium | Brand | 11 | $1,639 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 12 | $1,532 |
The 10 drugs with the highest cost, of 29 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 11 billing codesPaid by Medicare
$39,133
Medicare patients
287
Services billed
740
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 50% | |
| Diabetes | 47% | |
| Ischemic heart disease | 37% | |
| Chronic kidney disease | 35% | |
| Depression | 30% | |
| Heart failure | 26% | |
| Osteoporosis | 26% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in North Dakota
William Zaks
Endocrinology, Diabetes & Metabolism · Grand Forks, ND
Bilal Ahmed
Endocrinology, Diabetes & Metabolism · Bismarck, ND
Rodhan Khthir
Endocrinology, Diabetes & Metabolism · Bismarck, ND
Mario Rivera
Endocrinology, Diabetes & Metabolism · Fargo, ND
Raul Ruiz Esponda
Endocrinology, Diabetes & Metabolism · Fargo, ND
Soamsiri Niwattisaiwong
Endocrinology, Diabetes & Metabolism · Fargo, ND
Related records
Endocrinology, Diabetes & Metabolism in North Dakota
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in North Dakota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.